|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
selective serotonin reuptake inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
1987
|
|
gptkbp:ATCCode
|
gptkb:N06AB03
|
|
gptkbp:brand
|
gptkb:Prozac
gptkb:Rapiflux
gptkb:Sarafem
Selfemra
|
|
gptkbp:CASNumber
|
54910-89-3
|
|
gptkbp:cause
|
gptkb:serotonin_syndrome
QT prolongation
|
|
gptkbp:chemicalFormula
|
C17H18F3NO
|
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
hypersensitivity to fluoxetine
|
|
gptkbp:developedBy
|
gptkb:United_States
|
|
gptkbp:discoveredBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:discoveredIn
|
1972
|
|
gptkbp:eliminationHalfLife
|
1 to 3 days (parent), 7 to 15 days (norfluoxetine)
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fluoxetine
|
|
gptkbp:KEGGID
|
D00318
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin
|
|
gptkbp:MedlinePlusID
|
a689006
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
94.5%
|
|
gptkbp:PubChem_CID
|
CHEMBL27
3386
DB00472
|
|
gptkbp:riskFactor
|
increased risk of suicidal thoughts in young people
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
anxiety
headache
insomnia
dry mouth
sexual dysfunction
|
|
gptkbp:synonym
|
gptkb:N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
|
|
gptkbp:UNII
|
01K63SUP8D6
|
|
gptkbp:usedFor
|
gptkb:obsessive-compulsive_disorder
gptkb:panic_disorder
gptkb:major_depressive_disorder
gptkb:bulimia_nervosa
premenstrual dysphoric disorder
|
|
gptkbp:bfsParent
|
gptkb:CYP2D6
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|